Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).
Market Cap:3300M; Shares Outstanding:37.0M; Short Interest: 17.61%; Q3 2019(9/30/19): Cash 43.64M. Loss 19.14M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 127，no change
Shares hold: 18829.3k shares. no change
shares% hold: 54.56%，no change
2020.01.15: 2 Top Growth Stocks to Buy in January
2020.01.07: Axsome Therapeutics: Buy at the High?